Status:
COMPLETED
Proof-of-Concept Trial of a Positive Psychology Intervention for Caregivers of Patients Undergoing HSCT
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Caregiver
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Caregivers (i.e., family and friends) of patients with cancer are essential in providing care during cancer treatment. For patients who are undergoing a hematopoietic stem cell transplant/transplantat...
Detailed Description
The proposed project (PATH-C) entails two phases: 1. Phase one is an open-pilot trial in 5 caregivers of patients undergoing HSCT to refine the PATH intervention. 2. Phase two is single-arm open-pilo...
Eligibility Criteria
Inclusion
- Adult caregivers (≥18 years) of patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) at Dana-Farber Cancer Institute (DCFI).
- A relative or a friend who either lives with the patient or has in-person contact with him or her at least twice per week and is identified as the primary caregiver for HSCT.
- Ability to speak English and able to complete questionnaires with minimum assistance of an interpreter.
Exclusion
- Cognitive deficits impeding a caregiver's ability to provide informed consent or participate adequately in the study assessed via a commonly used 6-item cognitive assessment, the Brief Interview for Mental Status (BIMS) screening tool, which is sensitive and specific for screening for cognitive impairment in research subjects.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2024
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT05216978
Start Date
March 1 2022
End Date
April 30 2024
Last Update
July 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115